Presentation is loading. Please wait.

Presentation is loading. Please wait.

Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti.

Published byΚόριννα Αργυριάδης Modified over 5 years ago

Similar presentations

Presentation on theme: "Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti."— Presentation transcript:

1 Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti et al. N Engl J Med 2004; 351:1941

2 Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril or Placebo Piero Ruggenenti et al. N Engl J Med 2004; 351:1941

3 Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Verapamil or Placebo Piero Ruggenenti et al. N Engl J Med 2004; 351:1941

4 Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with or without ACE Inhibitors Piero Ruggenenti et al. N Engl J Med 2004; 351:1941

5 Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with or without Non-Dihydropyridine Calcium-Channel Blockers Piero Ruggenenti et al. N Engl J Med 2004; 351:1941

6 Trough Systolic and Diastolic Blood Pressure According to Treatment Group
Piero Ruggenenti et al. N Engl J Med 2004; 351:1941

Download ppt "Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti."

Similar presentations

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with chronic systolic heart failure.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with chronic systolic heart failure.
Montalescot G, et al. Lancet 2009;373:723-31. Trial profile Montalescot G, et al. Lancet 2009;373:723-31.

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:
NHANES III Prevalence of Hypertension* According to BMI

NHANES III Prevalence of Hypertension* According to BMI
The TRial Of Preventing HYpertension (TROPHY) TROPHY.

The TRial Of Preventing HYpertension (TROPHY) TROPHY.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:131-40.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.

Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.
Wald DS, et al. Am J Med 2009;122:290-300. Details of the 42 Trials Included in the Meta-analysis - Part I Wald DS, et al. Am J Med 2009;122:290-300.

Wald DS, et al. Am J Med 2009;122: Details of the 42 Trials Included in the Meta-analysis - Part I Wald DS, et al. Am J Med 2009;122:
Study design: a randomized placebo- controlled crossover trial of 2 periods of 4 weeks Nicole A.J. van der Linde, et al. Hypertension 2006;47;1125-1130.

Study design: a randomized placebo- controlled crossover trial of 2 periods of 4 weeks Nicole A.J. van der Linde, et al. Hypertension 2006;47;
NYHA III* or IV heart failure ACE-I + loop diuretic ± digoxn

NYHA III* or IV heart failure ACE-I + loop diuretic ± digoxn
Flowchart of participants

Flowchart of participants
All-cause mortality by treatment group

All-cause mortality by treatment group
Mean 24-Hour, Daytime, and Night Ambulatory Systolic BP, Diastolic BP, and PP Before (Week 0) and After (Week 12) NAG and Placebo Intake in 37 Hypertensive.

Mean 24-Hour, Daytime, and Night Ambulatory Systolic BP, Diastolic BP, and PP Before (Week 0) and After (Week 12) NAG and Placebo Intake in 37 Hypertensive.
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic

Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic
WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,
Mean BP from initial visit to four years

Mean BP from initial visit to four years
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.
Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors
Figure 5 Risk factor control in the intensive treatment group

Figure 5 Risk factor control in the intensive treatment group

Similar presentations

Ads by Google